Oncotarget a primarily oncology-focused, peer-reviewed, open access journal aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.
Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial , Introducing Oncotarget.
As of January 1, , Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed. Post-Publication Promotion Services. Impact Journals is a member of the Society for Scholarly Publishing.
As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI. Archis Bagati , Timothy C. Nikiforov , Jennifer Zirnheld and Shoshanna N. Nikiforov 1 , Jennifer Zirnheld 4 and Shoshanna N. Keywords: non-thermal plasma; gap junction; tirapazamine; melanoma; intercellular communication. Metastatic melanoma cells overexpressing gap junctions were assayed for their ability to propagate cell death by a novel combination therapy that generates reactive oxygen species ROS by both 1 non-thermal plasma NTP and 2 tirapazamine TPZ under hypoxic conditions.
Results demonstrate additive-to-synergistic effects of combination therapy compared to each agent individually. NTP induces highly localized cell death in target areas whereas TPZ partially reduces viability over the total surface area. Immune response was also elicited through differential regulation of cytokines and chemokines, suggesting potential for this therapy to induce a cytotoxic immune response with fewer side effects than current therapies.
